Therapy Areas: Cardiovascular
Dr. Reddy's Laboratories Launches Pemetrexed for Injection USP, in the US Market
1 June 2022 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of Alimta (pemetrexed for injection) in the US Market approved by the US Food and Drug Administration (USFDA), the company said.

The Alimta brand and generic had US sales of approximately USD 1239m MAT for the most recent twelve months ending in March 2022 according to IQVIA Health.

Dr. Reddy's Pemetrexed for Injection is supplied in 100 mg and 500 mg single-dose vials.
Click here for full prescribing information.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Its major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines